Although additional studies are required to evaluate the effectiveness of this ATF6-targeting strategy on tumor angiogenesis and tumor recurrence in relevant preclinical models, these results collectively suggest the potential of the ATF6-mediated transcriptional control of EGF expression as a target to prevent recurrent tumor formation. The gene discussed is EGF; the disease is neoplasm.